These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 831730)

  • 21. Effect of N-phosphonacetyl-L-aspartate and D-glucosamine on the incorporation of 5-fluorouridine into normal tissues and an adenocarcinoma in the rat.
    Erichsen C; Christensson PI; Jakobsson B; Eriksson G; Yngner T; Jönsson PE; Stenram U
    Anticancer Res; 1987; 7(1):77-80. PubMed ID: 3566186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
    Moyer JD; Smith PA; Levy EJ; Handschumacher RE
    Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
    Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
    Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
    Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
    Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
    Grant S; Rauscher F; Jakubowski A; Cadman E
    Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiproliferative agents and differential survival between normal and cancer cells.
    Tsuboi KK; Kwong LK
    Cancer Res; 1978 Nov; 38(11 Pt 1):3745-50. PubMed ID: 698934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation.
    Gao LJ; De Jonghe S; Daelemans D; Herdewijn P
    Bioorg Med Chem Lett; 2016 May; 26(9):2142-6. PubMed ID: 27032331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
    Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
    Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
    Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC
    Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
    Sieber SM; Botkin CC; Soong P; Lee EC; Whang-Peng J
    Teratology; 1980 Dec; 22(3):311-9. PubMed ID: 7233336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of N-(phosphonacetyl)-L-aspartate.
    Erlichman C; Strong JM; Wiernik PH; McAvoy LM; Cohen MH; Levine AS; Hubbard SM; Chabner BA
    Cancer Res; 1979 Oct; 39(10):3992-5. PubMed ID: 157801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate.
    Wiley RG; Gralla RJ; Casper ES; Kemeny N
    Ann Neurol; 1982 Aug; 12(2):175-83. PubMed ID: 7125606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
    Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
    Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carbamyl phosphate and glutamine stimulation of the gallbladder salt pump.
    Martin DW; Murphy B
    J Membr Biol; 1974; 18(3-4):231-42. PubMed ID: 4417724
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC; Markman M; Cleary S; Howell SB
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA; Durrani FA; Rustum YM
    Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.